tadalafil / Generic mfg. - LARVOL DELTA

Degradable Hydrogel Microspheres for Drug Delivery: In Vitro Performance and Influence of E-Beam Sterilization. (PubMed, AAPS PharmSciTech) - "The present work examines the in vitro drug delivery performance of degradable microspheres (DrugMic) composed of a crosslinked hydrogel of poly(ethylene glycol), with particular interest on the effect of e-beam sterilization on the stability of loaded active substances, i.e. niflumic acid (14% w/w), tadalafil (7% w/w), travoprost (0.2% w/w), buprenorphine (1.4% w/w), teicoplanin (6% w/w), and polymyxin B (5.6% w/w). DrugMic appears to be a suitable platform for sustained drug release. The loading mode can be adapted according to the stability of the drug to irradiation."

Journal • Preclinical

Juvenile Systemic Sclerosis Presenting With Severe Pulmonary Vascular Disease: ECMO Stabilization During Aggressive Therapy Resulting in a Favorable Outcome. (PubMed, Pulm Circ) - "Veno-arterial extracorporeal membranous oxygenation (VA-ECMO) and atrial stent placement facilitated treatment with pulse-dose steroids, mycophenolate mofetil, and B-cell depleting therapy to treat the underlying autoimmune inflammation and triple therapy with treprostinil, ambrisentan, and tadalafil for her pulmonary hypertension. At 9-month follow-up, her jSSc is well-controlled with complete resolution of her PH. This case demonstrates that multi-disciplinary treatment, including upfront multi-drug therapy for jSSC and PAH, that included VA-ECMO, may improve outcomes, particularly when treatment for underlying causes (in this case, jSSc) is just being initiated."

Journal • Cardiovascular • Critical care • Hypertension • Immunology • Inflammation • Pediatrics • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • Scleroderma • Systemic Sclerosis

Modulation of Genetic Markers of Fibrosis and Skin Score in Patients with Systemic Sclerosis Following Administration of Tadalafil (EULAR 2025) - "Tadalafil significantly reduced the skin fibrosis and mRNA expression of profibrotic genes in systemic sclerosis. It is a potential therapeutic option for skin fibrosis in systemic sclerosis."

Clinical • Cardiovascular • Fibrosis • Immunology • Infectious Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases • Rheumatology • Scleroderma • Septic Shock • Systemic Sclerosis • ACTA2 • COL1A1 • COL1A2 • CTGF • SIGLEC1 • THBS1

Comparing efficacy and safety of monotherapy and combination therapy with tadalafil, tamsulosin, and silodosin for distal ureteral stones: A systematic review and meta-analysis. (PubMed, Asian J Urol) - "It appears that tadalafil and silodosin have similar efficacy in SET and SER. All medical expulsive therapies had comparable safety."

Journal • Monotherapy • Retrospective data • Review • Pain • Renal Calculi

TADALAFIL TREATMENT IN PATIENTS WITH CEREBRAL SMALL VESSEL DISEASE: NEUROVASCULAR OUTCOMES FROM THE ETLAS-2 SUB-STUDY. (ESOC 2025) - "Whole-brain CBF was reduced in all participants compared to normal values for healthy persons. Three months of daily tadalafil treatment increased whole-brain CBF compared to placebo in participants with CSVD. There were no changes in other investigated neurovascular outcomes."

Clinical • Cardiovascular

TADALAFIL TREATMENT IN PATIENTS WITH CEREBRAL SMALL VESSEL DISEASE: THE ETLAS-2 RANDOMIZED CLINICAL TRIAL. (ESOC 2025) - "In participants with CSVD, adherence to tadalafil was significantly lower as compared to placebo and did not fulfil the prespecified compliance rate. We observed a non-significant reduction in WMH volume after tadalafil, which warrants larger studies with longer treatment and reduced doses to explore the potential benefits of tadalafil in CSVD."

Clinical • Cardiovascular

Assessing Medication Adherence to Tadalafil 5 mg Once Daily in Erectile Dysfunction: A Cross-Sectional Analysis. (PubMed, Pharmacol Res Perspect) - "Socioeconomic and clinical factors, patients' cognitive and sensory status, and perceptions regarding medications and healthcare providers significantly influence adherence. Physicians should exercise caution when prescribing tadalafil 5 mg OaD to patients with lower socioeconomic status, as they may be at higher risk for reduced MA."

Journal • Erectile Dysfunction

Membrane-Mediated Action of Phosphodiesterase 5 Inhibitors. (PubMed, Pharmaceutics) - "Background/Objectives: Phosphodiesterase 5 (PDE5) inhibitors, sildenafil, vardenafil, and tadalafil, activate the cyclic guanosine monophosphate pathway resulting in vascular smooth muscle relaxation. Moreover, improved nitric oxide flow through membrane may partially explain therapeutic action of these drugs. The presented results are useful for finding novel implications for PDE inhibitors."

Journal • Alzheimer's Disease • CNS Disorders • Oncology

Preparation and Evaluation of Tadalafil-Loaded Nanoemulgel for Transdermal Delivery in Cold-Induced Vasoconstriction: A Potential Therapy for Raynaud's Phenomenon. (PubMed, Pharmaceutics) - "Thermal imaging showed significant vasodilation comparable to standard 0.2% nitroglycerin ointment. Pharmacokinetic studies indicated improved transdermal absorption with a higher Cmax (2.13 µg/mL), a prolonged half-life (t1/2 = 16.12 h), and an increased AUC0-24 compared to an oral nanosuspension (p < 0.001). The developed TDL nanoemulgel demonstrated effective transdermal delivery and significant potential as a patient-friendly therapeutic approach for Raynaud's phenomenon, offering an alternative to conventional oral therapy."

Journal • Cardiovascular • Rheumatology

Long-term Treatment of Single-tablet Combination of Macitentan and Tadalafil in Pulmonary Arterial Hypertension (PAH): Final Results From the A DUE Open-label Extension (ATS 2025) - P3 | "Adult PAH patients randomized to M/T FDC, macitentan, or tadalafil during the DB were transitioned to the OL, receiving M/T FDC. The vast majority of patients were alive at the end of the study. Improvements in 6MWD and NT-proBNP observed in the DB with M/T FDC were maintained during the 24-month OL."

Clinical • Late-breaking abstract • Anemia • Cardiovascular • Hematological Disorders • Hepatology • Hypotension • Pulmonary Arterial Hypertension • Respiratory Diseases • NPPB

Granulomatous Interstitial Lung Disease: A Case Series in an Australian Tertiary Centre (ATS 2025) - "Tadalafil monotherapy and Rituximab were commenced. Conclusion GLILD is an important manifestation of a rare condition. Early recognition is critical; close surveillance and initiation of immunosuppression can stabilise or improve symptoms and spirometry."

Clinical • B Cell Lymphoma • Cardiovascular • Cough • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Infectious Disease • Interstitial Lung Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Pain • Primary Immunodeficiency • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

A Paradigm Shift in Acute Exacerbation Management of Interstitial Lung Disease: Plasmapheresis as Standard Therapy in Anti-synthetase Syndrome (ATS 2025) - "CLINICAL CASE PRESENTATION A 52-year-old female with ASSD (positive anti-Jo-1 and anti-SSA antibodies) and pre-capillary pulmonary arterial hypertension (PAH) managed with tadalafil and macitentan experienced her first ILD exacerbation in 2022. This event required invasive mechanical ventilation, systemic steroids, cyclophosphamide (CYC), and intravenous immunoglobulin (IVIG), resulting in clinical stabilization. However, despite ongoing treatment with CYC, methotrexate (MTX), and a steroid-tapering regimen, she developed a rapidly progressive ILD phenotype. Imaging and lung function tests (FVC dropped to 24%) confirmed disease progression, leading to a regimen of rituximab (RTX) and CYC...Over the next year, her regimen included MMF, tacrolimus, prednisone, nintedanib, and PCP prophylaxis...This case emphasizes the need for further research on combined immunosuppressive approaches, especially in settings with limited access to lung transplantation. Controlled trials are..."

Cardiovascular • Fibrosis • Immunology • Infectious Disease • Interstitial Lung Disease • Myositis • Pneumonia • Pulmonary Arterial Hypertension • Pulmonary Disease • Rare Diseases • Respiratory Diseases • Rheumatology

Varying Efficacy of Tadalafil in Bone Morphogenetic Protein Receptor 2 Mutation Carriers Compared to Wild Type Rats in an Experimental Model of Pulmonary Arterial Hypertension (ATS 2025) - "In BMPR2Δex4 rats, we observed the development of a more severe pathology characterized by pronounced cardiovascular remodeling, which is often absent in mouse genetic models. This makes BMPR2Δex4 rats a better model for testing new therapeutic agents and for investigating the underlying role of the BMPR2/TGFbeta pathway in PAH."

Preclinical • Cardiovascular • Congestive Heart Failure • Heart Failure • Pulmonary Arterial Hypertension • Respiratory Diseases • TGFB1

Effective Pharmacotherapy in Hereditary Pulmonary Arterial Hypertension: A Case of BMPR2 Mutation (ATS 2025) - "An initial vasodilator challenge with Flolan improved cardiac output and reduced PVR, but pulmonary pressures remained high, necessitating a comprehensive treatment plan.The patient was started on tadalafil, a phosphodiesterase-5 inhibitor, known for reducing pulmonary pressures and enhancing exercise capacity in PAH. However, initial trials with the endothelin receptor antagonist macitentan were unsuccessful due to side effects, including significant facial and lower extremity swelling. Consequently, ambrisentan, another endothelin receptor antagonist, was considered as a potential alternative for better tolerance...Additionally, the patient's treatment included Bumex diuretics to manage fluid overload and losartan for blood pressure control...The addition of selexipag significantly improved her quality of life. This case highlights the critical role of pharmacotherapy in managing PAH associated with BMPR2 mutation."

Clinical • Cardiovascular • Congestive Heart Failure • Gastrointestinal Disorder • Heart Failure • Hematological Disorders • Hypertension • Immunology • Inflammatory Arthritis • Lupus • Obesity • Pulmonary Arterial Hypertension • Pulmonary Embolism • Respiratory Diseases

A Case of Dasatinib Induced Pulmonary Hypertension (ATS 2025) - "Patient was managed with diuretics, and Macitentan and tadalafil were started. Rapid recurrence of symptoms of PH have occurred in one patient who was restarted on Dasatinib. As PH is a serious adverse effect, it is crucial for physicians to be aware of this risk, to be able to appropriately evaluate, monitor and manage these patients."

Clinical • Cardiovascular • Heart Failure • Immunology • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

A Challenging Diagnosis: When to Suspect Pulmonary Veno-occlusive Disease (ATS 2025) - "Tadalafil was initially started followed by macitentan, which were associated with worsening hypoxemia and dyspnea...She was discharged with plans to continue low dose outpatient epoprostenol and start sotatercept...Management is challenging given ineffective or potentially harmful responses to PAH-directed therapies, though some do respond to a variable extent. As suggested here, close supervision during epoprostenol infusion adds to the limited body of evidence supporting such endeavors when initiating vasodilatory therapies in patients with suspected PVOD."

Cardiovascular • Hepatology • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Delivering Against the Odds: A Case Series of Successful Outcomes in Pulmonary Arterial Hypertension During Childbirth (ATS 2025) - "She was on treprostinil infusion and tadalafil 40 mg daily, which were maintained during hospitalization...Upon admission, she was in cardiogenic shock with acute RHF requiring epinephrine and vasopressin for support. She was started on macitentan 10 mg daily, sildenafil 20 mg three times daily, inhaled nitric oxide, and a treprostinil infusion...The use of tailored PAH therapies and meticulous delivery planning underscores the necessity of individualized care in high-risk cases. These successful outcomes demonstrate that, with expert management, favorable maternal and fetal outcomes are achievable in cases once considered impossible."

Clinical • Anesthesia • Cardiovascular • Congestive Heart Failure • Heart Failure • Hypotension • Immunology • Inflammatory Arthritis • Lupus • Obstetrics • Pulmonary Arterial Hypertension • Respiratory Diseases • Rheumatoid Arthritis • Rheumatology • Systemic Lupus Erythematosus

The Phourth Pathway in PAH: Experience in the "Underserved" Central Valley of California (ATS 2025) - "Sotatercept (SOT) is the new activin inhibitor recently added as the fourth pathway...Case 1: A 45-year-old African-American female with WHO group 1 CTD-PAH reported worsening symptoms despite triple therapy (Parenteral prostacyclin therapy (PPT) + Endothelin receptor agonist (ERA) + Tadalafil (TAD)...Case 3: A 53-year-old Hispanic male with IPAH was on Triple combo treatment (Oral prostacyclin + ERA + Riociguat (Rio))... These cases illustrate favorable responses to SOT in patients with progressive PAH. Often, Symptom improvement was perceived as soon as after 1st dose. Of 4 patients, SOT had to be stopped in 1 patient due to significant Thrombocytopenia despite favorable clinical response."

Cardiovascular • Congestive Heart Failure • Heart Failure • Hematological Disorders • Immunology • Inflammatory Arthritis • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • Sjogren's Syndrome • Thrombocytopenia

Unmasking Pulmonary Hypertension in Hereditary Hemochromatosis: A Patient's Story (ATS 2025) - "Combination pulmonary vasodilator therapy with tadalafil and treprostinil was initiated along with optimization of fluid balance and regular phlebotomies. In cases where phlebotomy is insufficient, iron chelation therapy may be considered. Early diagnosis and treatment with pulmonary vasodilators can alleviate symptoms and improve survival."

Clinical • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Diabetes • Fibrosis • Genetic Disorders • Heart Failure • Hematological Disorders • Hepatology • Hypertension • Immunology • Metabolic Disorders • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Unmasked Pulmonary Hypertension After Successful Liver Transplantation (ATS 2025) - "Case Descriptions: Patient 1: A 60-year-old woman with cirrhosis secondary to metabolic dysfunction-associated fatty liver disease and mild PoPH on sildenafil underwent uncomplicated LT...She was treated with ambrisentan and tadalafil with clinical improvement, and eventually underwent renal transplantation with fistula ligation...Early recognition of PH in the post-operative period, especially in the setting of pre-transplant HPS, is vital to ensure timely treatment of these patients. Further cases should be identified and described to help clarify the pathophysiological basis for this phenomenon."

Cardiovascular • Congestive Heart Failure • Fibrosis • Heart Failure • Hepatitis C • Hepatology • Immunology • Infectious Disease • Inflammation • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Nephrology • Pulmonary Arterial Hypertension • Pulmonary Disease • Renal Disease • Respiratory Diseases • Transplantation

Pulmonary Veno-occlusive Disease (PVOD) Contributing to Pulmonary Arterial Hypertension in an 11-year Old Boy With a Heterozygous Pathogenic Variant in EIF2AK4 (ATS 2025) - "He was hospitalized in Mexico where a repeat ECHO confirmed PH, and he was started on Sildenafil and Budesonide...He had worsening heart function on ECHO and started on triple therapy with treprostinil, ambrisentan, tadalafil and nitric oxide therapy. He was discharged home August 2024 on 1L of supplemental oxygen via nasal cannula, furosemide daily, and triple therapy with ambristentan, tadalafil and selexipag...Lung transplant remains the only definitive treatment, therefore early diagnosis and management is vital. As seen in this case, close outpatient follow up played a key role in the optimal management of PVOD despite fragmented care."

Asthma • Cardiovascular • Fatigue • Hepatology • Immunology • Infectious Disease • Influenza • Pediatrics • Pulmonary Arterial Hypertension • Respiratory Diseases

Daily phosphodiesterase type 5 inhibitors plus acetylsalicylic acid improve curvature progression and pain intensity during the active phase of peyronie's disease. (PubMed, Urologia) - "We performed a retrospective cohort study of 161 patients affected by PD in active stage and erectile dysfunction treated with tadalafil 5 mg once daily were divided in two groups. In the analysis of our secondary endpoint, we demonstrated a significantly lower intensity of pain during erection in GB (1.43 ± 1.12) compared GA (1.89 ± 1.25; p < 0.001). We observed that the regular use of this therapeutic combination significantly provided more benefit in patients with active stage PD in terms of penile deformity, pain, and discomfort during penetrative intercourses."

Journal • Erectile Dysfunction • Pain

Cutting-edge assays for mirabegron and tadalafil combo therapy for benign prostatic hyperplasia; insilico kinetics approach; multi trait sustainability assessment. (PubMed, BMC Chem) - "Furthermore, artificial intelligence was employed through an online tool to ensure that there were no potential drug-drug interactions between MIR and TAD, offering an additional layer of safety in clinical applications. This research contributes to the enhancement of quality control for patients undergoing combination therapy with MIR and TAD and stability testing."

Journal • Benign Prostatic Hyperplasia • Overactive Bladder

Vitamin D as an add-on therapy to phosphodiesterase-5 inhibitor in experimental pulmonary arterial hypertension (HEART FAILURE 2025) - "Also, recent evidence suggests that vitD deficiency may cause insufficient response to phosphodiesterase-5 inhibitors (PDE5i), such as sildenafil, in some patients with PAH...Following this, vitD deficient rats with PAH were housed in room air and divided into two groups: (a) daily tadalafil therapy (oral; 10mg/kg) + continued vitD-free diet (n=9) or (b) daily tadalafil therapy (oral; 10mg/kg) + single oral dose of 50,000 IU/Kg of vitD plus standard diet (n=9) for four weeks... The recovery of vitD status might help to improve responsiveness to PDE5i. These data suggest a potential benefit of vitD as add-on therapy in the context of PAH patients with vitD deficiency. Besides comorbidities, detecting clinical traits, as vitD deficiency, which are associated with an unfavorable response to PDE5i treatment could allow individualized treatment approaches."

Cardiovascular

A Budget Impact Analysis of Introducing OPSYNVI for the Treatment of Adult Patients Diagnosed With Pulmonary Arterial Hypertension (ISPOR 2025) - "Comparators included macitentan, ambrisentan, bosentan, tadalafil, sildenafil, and an ERA + PDE5i loose dose combination. Introducing OPSYNVI results in a minimal budget impact for both commercial and Medicare advantage plans. Despite its higher monthly costs, our model demonstrates that OPSYNVI could reduce hospitalization days, readmissions, and patients’ progression to prostanoid. Given that PAH is a rare, progressive, fatal disease, adding OPSYNVI to a plan’s formulary has negligible costs while potentially improving outcomes."

Clinical • HEOR • Cardiovascular • Pulmonary Arterial Hypertension • Respiratory Diseases